Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 3/20 | 0.51 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.42 |
| ▸ | FER | P16591 | 3/20 | 0.38 |
| ▸ | SYK | P43405 | 8/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | LYN | P07948 | 1/20 | 0.37 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | BCDIN3D | Q7Z5W3 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7783143 | 1.00 | CRHR1 (0.51) | CRHR1KAT2BFERSYKJAK2 | |
| SCHEMBL7681407 | 0.85 | CRHR1 (0.54) | CRHR1 | |
| SCHEMBL7557048 | 0.79 | CRHR1 (0.52) | CRHR1 | |
| SCHEMBL7788898 | 0.78 | CRHR1 (0.48) | CRHR1 | |
| SCHEMBL7791098 | 0.77 | CRHR1 (0.47) | CRHR1 | |
| SCHEMBL7788903 | 0.77 | CRHR1 (0.49) | CRHR1 | |
| SCHEMBL7788894 | 0.77 | CRHR1 (0.62) | CRHR1 | |
| SCHEMBL7788924 | 0.76 | CRHR1 (0.47) | CRHR1SYKKCNH2BCDIN3D | |
| SCHEMBL7788921 | 0.75 | CRHR1 (0.49) | CRHR1 | |
| SCHEMBL7792967 | 0.75 | CRHR1 (0.57) | CRHR1BCDIN3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010031758-A1 | Substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives: selective neuropeptide Y receptor ligands | NEUROGEN CORPORATION | 2001-10-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031758-A1 | Substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives: selective neuropeptide Y receptor ligands | NPY1R, NPY2R, NPY5R | CRHR1 33/4885KAT2B 3620/4885FER 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.